乐动手机网页版登录入口-乐动（中国）

Beihai Biotech announced that its innovative cancer drug, BH009 (marketed as BEIZRAY), has received approval from the U.S. Food and Drug Administration (FDA)

2024-10-31
U.S. FDA Formally Accepts Beihai Biotech's New Drug Application for Innovative Oncology Drug BH009 (BEIZRAY™)

2024-01-04
Beihai Biotech Founder Dr. Sun Invited to Keynote 'Wisdom in China' Summit at Renmin University Business School

2023-12-26
Beihai Biotech Successfully Concludes Series C Funding, Expediting BH009 Commercialization and Advancing Clinical Trials for Innovative Drug Candidates

2023-12-19
Beihai Biotech Secures “Drug Manufacturing Certificate”

2023-06-15
Landmark Clinical Research Findings of Beihai Biotech's BH009 Unveiled at ASCO 2023

2023-06-12
乐动手机网页版登录入口用于治疗晚期三阴性乳腺癌的创新药物BH009获批开展II期临床试验

2023-04-10
乐动手机网页版登录入口BH009新药项目在晚期头颈部鳞癌和卵巢癌患者中的I期临床试验完成首例患者给药

2023-03-09

开云网页版登录入口 | 安博网页版 | 华亿体育平台_华亿体育(中国) | 华体平台_华体(中国) | 开云电子（中国）官方网站 | 九州体育（JiuZhou Sports）官方网站 | 万博 | 开云登陆入口 | 开云在线开户 |